Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency


Cite item

Full Text

Abstract

Mitapivat is an orally bioavailable small molecule allosteric activator of pyruvate kinase. It was approved by the US FDA on February 17, 2022, and the European Union in November 2022 for the treatment of hemolytic anemia in adult patients with pyruvate kinase deficiency. In this short perspective, physicochemical properties, synthesis, dosage and administration, mechanism of action, pharmacodynamics, pharmacokinetics, drug interactions, and adverse reactions of mitapivat are described.

About the authors

Surya De

Department of Chemistry,, Conju-Probe

Author for correspondence.
Email: info@benthamscience.net

References

  1. Koralkova, P.; van Solinge, W.W.; van Wijk, R. Rare hereditary red blood cell enzymopathies associated with hemolytic anemia - pathophysiology, clinical aspects, and laboratory diagnosis. Int. J. Lab. Hematol., 2014, 36(3), 388-397. doi: 10.1111/ijlh.12223 PMID: 24750686
  2. Kanno, H.; Fujii, H.; Miwa, S. Structural analysis of human pyruvate kinase L-gene and identification of the promoter activity in erythroid cells. Biochem. Biophys. Res. Commun., 1992, 188(2), 516-523. doi: 10.1016/0006-291X(92)91086-6 PMID: 1445295
  3. Secrest, M.H.; Storm, M.; Carrington, C.; Casso, D.; Gilroy, K.; Pladson, L.; Boscoe, A.N. Prevalence of pyruvate kinase deficiency: A systematic literature review. Eur. J. Haematol., 2020, 105(2), 173-184. doi: 10.1111/ejh.13424 PMID: 32279356
  4. Bianchi, P.; Fermo, E.; Lezon-Geyda, K.; Beers, E.J.; Morton, H.D.; Barcellini, W.; Glader, B.; Chonat, S.; Ravindranath, Y.; Newburger, P.E.; Kollmar, N.; Despotovic, J.M.; Verhovsek, M.; Sharma, M.; Kwiatkowski, J.L.; Kuo, K.H.M.; Wlodarski, M.W.; Yaish, H.M.; Holzhauer, S.; Wang, H.; Kunz, J.; Addonizio, K.; Al-Sayegh, H.; London, W.B.; Andres, O.; Wijk, R.; Gallagher, P.G.; Grace, R.F.F. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am. J. Hematol., 2020, 95(5), 472-482. doi: 10.1002/ajh.25753 PMID: 32043619
  5. Rab, M.A.E.; Van Oirschot, B.A.; Kosinski, P.A.; Hixon, J.; Johnson, K.; Chubukov, V.; Dang, L.; Pasterkamp, G.; Van Straaten, S.; Van Solinge, W.W.; Van Beers, E.J.; Kung, C.; Van Wijk, R. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica, 2020, 106(1), 238-249. doi: 10.3324/haematol.2019.238865 PMID: 31974203
  6. Glenthøj, A.; van Beers, E.J.; Al-Samkari, H.; Viprakasit, V.; Kuo, K.H.M.; Galactéros, F.; Chonat, S.; Porter, J.; Zagadailov, E.; Xu, R.; Oluyadi, A.; Hawkins, P.; Gheuens, S.; Beynon, V.; Barcellini, W. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): A multicentre, open-label, single-arm, phase 3 trial. Lancet Haematol., 2022, 9(10), e724-e732. doi: 10.1016/S2352-3026(22)00214-9 PMID: 35988546
  7. Kuo, K.H.M.; Layton, D.M.; Lal, A.; Al-Samkari, H.; Bhatia, J.; Kosinski, P.A.; Tong, B.; Lynch, M.; Uhlig, K.; Vichinsky, E.P. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: An open-label, multicentre, phase 2 study. Lancet, 2022, 400(10351), 493-501. doi: 10.1016/S0140-6736(22)01337-X PMID: 35964609
  8. Shah, A.J.; Schwartz, J.D.; Segovia, J.C. Mitapivat versus placebo for pyruvate kinase deficiency. N. Engl. J. Med., 2022, 386(26), 2538-2539. doi: 10.1056/NEJMc2206275 PMID: 35767453
  9. Kung, C.; Hixon, J.; Kosinski, P.A.; Cianchetta, G.; Histen, G.; Chen, Y.; Hill, C.; Gross, S.; Si, Y.; Johnson, K.; DeLaBarre, B.; Luo, Z.; Gu, Z.; Yao, G.; Tang, H.; Fang, C.; Xu, Y.; Lv, X.; Biller, S.; Su, S.S.M.; Yang, H.; Popovici-Muller, J.; Salituro, F.; Silverman, L.; Dang, L. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood, 2017, 130(11), 1347-1356. doi: 10.1182/blood-2016-11-753525 PMID: 28760888
  10. Al-Samkari, H.; van Beers, E.J. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias. Ther. Adv. Hematol., 2021, 12. doi: 10.1177/20406207211066070 PMID: 34987744
  11. Sizemore, J.; Guo, L.; Mirmehrabi, M.; Su, Y. Crystalline Forms of N-(4-(4-(Cyclopropylmethyl) Piperazine-1-Carbonyl)Phenyl)Quinoline-8-Sulfonamide. WO2019104134A1, 2019.
  12. Matte, A.; Federti, E.; Kung, C.; Kosinski, P.A.; Narayanaswamy, R.; Russo, R.; Federico, G.; Carlomagno, F.; Desbats, M.A.; Salviati, L.; Leboeuf, C.; Valenti, M.T.; Turrini, F.; Janin, A.; Yu, S.; Beneduce, E.; Ronseaux, S.; Iatcenko, I.; Dang, L.; Ganz, T.; Jung, C.L.; Iolascon, A.; Brugnara, C.; De Franceschi, L. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model. J. Clin. Invest., 2021, 131(10), e144206. doi: 10.1172/JCI144206 PMID: 33822774
  13. Idris, I.M.; Burnett, A.L.; DeBaun, M.R. Epidemiology and treatment of priapism in sickle cell disease. Hematology, 2022, 2022(1), 450-458. doi: 10.1182/hematology.2022000380 PMID: 36485155
  14. Musallam, K.M.; Taher, A.T.; Cappellini, M.D. Right in time: Mitapivat for the treatment of anemia in α - and β-thalassemia. Cell Rep. Med., 2022, 3(10), 100790. doi: 10.1016/j.xcrm.2022.100790 PMID: 36260990
  15. Xu, J.Z.; Conrey, A.; Frey, I.; Gwaabe, E.; Menapace, L.A.; Tumburu, L.; Lundt, M.; Lequang, T.; Li, Q.; Glass, K.; Dunkelberger, E.B.; Iyer, V.; Mangus, H.; Kung, C.; Dang, L.; Kosinski, P.A.; Hawkins, P.; Jeffries, N.; Eaton, W.A.; Lay Thein, S. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood, 2022, 140(19), 2053-2062. doi: 10.1182/blood.2022015403 PMID: 35576529
  16. van Dijk, M.J.; Rab, M.A.E.; van Oirschot, B.A.; Bos, J.; Derichs, C.; Rijneveld, A.W.; Cnossen, M.H.; Nur, E.; Biemond, B.J.; Bartels, M.; Jans, J.J.M.; van Solinge, W.W.; Schutgens, R.E.G.; van Wijk, R.; van Beers, E.J. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study. Am. J. Hematol., 2022, 97(7), E226-E229. doi: 10.1002/ajh.26554 PMID: 35384026
  17. Langer, A.L. Esrick, E.B. β-Thalassemia: Evolving treatment options beyond transfusion and iron chelation. Hematology, 2021, 2021(1), 600-606. doi: 10.1182/hematology.2021000313 PMID: 34889443

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers